![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GABPA |
Gene summary for GABPA |
![]() |
Gene information | Species | Human | Gene symbol | GABPA | Gene ID | 2551 |
Gene name | GA binding protein transcription factor subunit alpha | |
Gene Alias | E4TF1-60 | |
Cytomap | 21q21.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A8IE48 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2551 | GABPA | male-WTA | Human | Thyroid | PTC | 1.85e-21 | 1.05e-01 | 0.1037 |
2551 | GABPA | PTC01 | Human | Thyroid | PTC | 3.85e-05 | -2.74e-02 | 0.1899 |
2551 | GABPA | PTC04 | Human | Thyroid | PTC | 4.74e-08 | 5.53e-02 | 0.1927 |
2551 | GABPA | PTC05 | Human | Thyroid | PTC | 1.95e-09 | 2.15e-01 | 0.2065 |
2551 | GABPA | PTC06 | Human | Thyroid | PTC | 2.84e-17 | 2.61e-01 | 0.2057 |
2551 | GABPA | PTC07 | Human | Thyroid | PTC | 1.20e-14 | 2.06e-01 | 0.2044 |
2551 | GABPA | ATC12 | Human | Thyroid | ATC | 7.30e-07 | 1.97e-02 | 0.34 |
2551 | GABPA | ATC13 | Human | Thyroid | ATC | 6.82e-24 | 5.14e-01 | 0.34 |
2551 | GABPA | ATC2 | Human | Thyroid | ATC | 5.78e-05 | 4.00e-01 | 0.34 |
2551 | GABPA | ATC4 | Human | Thyroid | ATC | 2.71e-09 | 5.52e-02 | 0.34 |
2551 | GABPA | ATC5 | Human | Thyroid | ATC | 9.84e-28 | 5.76e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0001701111 | Thyroid | PTC | in utero embryonic development | 175/5968 | 367/18723 | 1.40e-10 | 4.73e-09 | 175 |
GO:0030099113 | Thyroid | PTC | myeloid cell differentiation | 160/5968 | 381/18723 | 1.75e-05 | 1.82e-04 | 160 |
GO:000182513 | Thyroid | PTC | blastocyst formation | 22/5968 | 38/18723 | 8.19e-04 | 5.07e-03 | 22 |
GO:00018246 | Thyroid | PTC | blastocyst development | 49/5968 | 106/18723 | 1.37e-03 | 7.72e-03 | 49 |
GO:000170126 | Thyroid | ATC | in utero embryonic development | 183/6293 | 367/18723 | 6.62e-11 | 2.11e-09 | 183 |
GO:003009933 | Thyroid | ATC | myeloid cell differentiation | 170/6293 | 381/18723 | 4.26e-06 | 4.68e-05 | 170 |
GO:000182414 | Thyroid | ATC | blastocyst development | 53/6293 | 106/18723 | 3.48e-04 | 2.16e-03 | 53 |
GO:000182521 | Thyroid | ATC | blastocyst formation | 23/6293 | 38/18723 | 6.05e-04 | 3.44e-03 | 23 |
GO:1903706112 | Thyroid | ATC | regulation of hemopoiesis | 148/6293 | 367/18723 | 3.87e-03 | 1.68e-02 | 148 |
GO:0045637113 | Thyroid | ATC | regulation of myeloid cell differentiation | 89/6293 | 210/18723 | 4.75e-03 | 1.96e-02 | 89 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GABPA | SNV | Missense_Mutation | c.718N>A | p.Leu240Ile | p.L240I | Q06546 | protein_coding | deleterious(0.02) | probably_damaging(0.912) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
GABPA | SNV | Missense_Mutation | rs749270145 | c.551A>G | p.Tyr184Cys | p.Y184C | Q06546 | protein_coding | tolerated(0.16) | probably_damaging(0.91) | TCGA-CI-6620-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Ancillary | leucovorin | PD |
GABPA | SNV | Missense_Mutation | c.1088N>A | p.Arg363His | p.R363H | Q06546 | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-F5-6864-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
GABPA | SNV | Missense_Mutation | novel | c.1292N>A | p.Leu431His | p.L431H | Q06546 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.615) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GABPA | SNV | Missense_Mutation | novel | c.1235N>T | p.Ala412Val | p.A412V | Q06546 | protein_coding | deleterious(0.04) | benign(0.395) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
GABPA | SNV | Missense_Mutation | c.350C>T | p.Ala117Val | p.A117V | Q06546 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GABPA | SNV | Missense_Mutation | rs759588641 | c.640A>G | p.Thr214Ala | p.T214A | Q06546 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GABPA | SNV | Missense_Mutation | c.160C>G | p.Leu54Val | p.L54V | Q06546 | protein_coding | tolerated(0.06) | possibly_damaging(0.628) | TCGA-AP-A0L8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
GABPA | SNV | Missense_Mutation | novel | c.21G>T | p.Glu7Asp | p.E7D | Q06546 | protein_coding | tolerated_low_confidence(0.22) | possibly_damaging(0.899) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GABPA | SNV | Missense_Mutation | novel | c.606N>T | p.Met202Ile | p.M202I | Q06546 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2551 | GABPA | TRANSCRIPTION FACTOR | QUERCETIN | QUERCETIN | 17462537 | |
2551 | GABPA | TRANSCRIPTION FACTOR | CISPLATIN | CISPLATIN | 18036733 | |
2551 | GABPA | TRANSCRIPTION FACTOR | DOX | 17081560 | ||
2551 | GABPA | TRANSCRIPTION FACTOR | CSA | CYCLOSPORINE | 16612258 |
Page: 1 |